| Name | Title | Contact Details |
|---|
Updates, earnings and commercializationListen to the audio recording of our recent shareholder call where we discussed the latest updates, gave an overview of our earnings report and highlighted the commercialization efforts underway at Predictive Onco...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Eclectic Institute is a Sandy, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hoechst AG is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.